Quarterly report pursuant to Section 13 or 15(d)

Segment Information (Tables)

Segment Information (Tables)

3 Months Ended

Sep. 30, 2014

Financial Information Relating to Reportable Segments

Following is financial information relating to the Company’s reportable segments (in thousands):


	Quarter Ended
	September 30,
	2014			2013
Net sales:
Biotechnology	$	81,468		$	73,190
Clinical Controls		14,095			12,478
Protein Platforms		12,914			0

Consolidated net sales	$	108,477		$	85,668

Segment operating income
Biotechnology	$	42,020		$	40,988
Clinical Controls		4,535			4,019
Protein Platforms		2,604			0

Subtotal reportable segments		49,159			45,007
Cost recognized on sale of acquired inventory		(3,167	)		(1,731	)
Amortization of acquisition related intangible assets		(5,728	)		(2,188	)
Corporate selling, general and administrative expenses		(2,678	)		(1,165	)
Acquisition related expenses		(2,370	)		(532	)

Consolidated operating income	$	35,216		$	39,391

- Definition

Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.

+ References + Details